Companies Immix Biopharma, Inc.
Immix Biopharma (IMMX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Immix Biopharma, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,129,881FY2023
- $1,267,158FY2024
- $1,352,854FY2025
CEO total pay was $1,352,854 in fiscal 2025, up from $1,267,158 in fiscal 2024.
FY2025: salary $475,000 · bonus $0 · stock awards $0 · option awards $592,854
Order IMMX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gabriel Morris | $475,000 | $0 | $0 | $592,854 | $285,000 | $0 | $0 | $1,352,854 |
| Chief Financial Officer, President and Director | ||||||||
| Ilya Rachman | 475,000 | 0 | 0 | 592,854 | 285,000 | 0 | 0 | 1,352,854 |
| Chief Executive Officer, Chief Scientific Officer and Chairman | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gabriel Morris | $1,352,854 | $1,267,158 | $1,129,881 | ↑ +85,696 |
| Ilya Rachman | 1,352,854 | 1,267,158 | 1,129,881 | ↑ +85,696 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gabriel Morris | OPTION | 2025-06-20 | — | — | 340,000 | — | $592,584 |
| Ilya Rachman | OPTION | 2025-06-20 | — | — | 340,000 | — | 592,584 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gabriel Morris | $0 | $0 | $592,584 | 0.0% |
| Ilya Rachman | 0 | 0 | 592,584 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ilya Rachman | Option | 36,458 | 2.64 | — |
| Gabriel Morris | Option | 36,458 | 2.64 | — |
| Ilya Rachman | Option | 122,083 | 1.86 | — |
| Gabriel Morris | Option | 122,083 | 1.86 | — |
| Ilya Rachman | Option | 212,500 | 2.04 | — |
| Gabriel Morris | Option | 212,500 | 2.04 | — |
| Ilya Rachman | Option | 297,500 | 2.24 | — |
| Gabriel Morris | Option | 297,500 | 2.24 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nancy ChangNot independent | $10,000 | $0 | $220,237 | — | $227,960 | $458,197 |
| Helen C. AdamsIndependent · Lead Independent Director · Audit (Chair) | 72,500 | 0 | 53,496 | — | 0 | 125,996 |
| Jane BuchanIndependent · Audit · Compensation · Nominating/Governance (Chair) | 60,500 | 0 | 53,496 | — | 0 | 113,996 |
| Magda MarquetIndependent · Compensation (Chair) · Nominating/Governance | 54,000 | 0 | 53,496 | — | 0 | 107,496 |
| Carey NgIndependent · Audit | 47,500 | 0 | 53,496 | — | 0 | 100,996 |
| Jason HsuIndependent · Compensation | 42,250 | 0 | 53,496 | — | 1,750 | 97,496 |
| Yekaterina ChudnovskyIndependent · Nominating/Governance | 42,000 | 0 | 53,496 | — | 0 | 95,496 |
| Ilya RachmanEmployee director · Board Chair | — | — | — | — | — | 0 |
| Gabriel MorrisEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $80,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 17,500 / 10,000 / 7,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $328,750 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $229,710 |
| Total cost of the board | $558,460 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Immix Biopharma as a peer
Companies that benchmark against IMMX
No companies currently name IMMX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immix Biopharma, Inc. | 2025 | Ilya Rachman | $475,000 | $0 | $592,854 | $285,000 | $1,352,854 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-22 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-22 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (18 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Gabriel Morris. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 18. As printed: 1,352,854. View filing ↗
- Section 01, Ilya Rachman. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 18. As printed: 1,352,854. View filing ↗
- Section 03, Gabriel Morris OPTION. DEF 14A, filed 2026-04-06. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ilya Rachman OPTION. DEF 14A, filed 2026-04-06. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Nancy Chang. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 458,197. View filing ↗
- Section 08, Helen C. Adams. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 125,996. View filing ↗
- Section 08, Jane Buchan. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 113,996. View filing ↗
- Section 08, Magda Marquet. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 107,496. View filing ↗
- Section 08, Carey Ng. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 100,996. View filing ↗
- Section 08, Jason Hsu. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 97,496. View filing ↗
- Section 08, Yekaterina Chudnovsky. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 95,496. View filing ↗
- Section 08, Ilya Rachman. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Gabriel Morris. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-04-06. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 328,750 + equity 0 + all other 229,710 = 558,460, summed across the director compensation table rows.
- Immix Biopharma, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Immix Biopharma, Inc.'s own proxy. As printed: 1,352,854. View filing ↗